Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PolyPid Ltd PYPD

Healthcare Biotechnology
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Recent & Breaking News (NDAQ:PYPD)

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 8, 2023

PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

GlobeNewswire January 31, 2023

PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

GlobeNewswire January 24, 2023

PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire January 3, 2023

PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

GlobeNewswire December 12, 2022

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

GlobeNewswire December 9, 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

GlobeNewswire November 29, 2022

PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 9, 2022

PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022

GlobeNewswire October 26, 2022

PolyPid Announces Cost Reduction Plan

GlobeNewswire October 20, 2022

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire September 28, 2022

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire September 19, 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

GlobeNewswire September 12, 2022

PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire September 2, 2022

PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

GlobeNewswire August 30, 2022

PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 10, 2022

PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe

GlobeNewswire August 3, 2022

PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022

GlobeNewswire July 27, 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

GlobeNewswire July 25, 2022

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

GlobeNewswire July 5, 2022